MedTrace Logo

Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors

NCT01118611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-05-01

No results posted yet for this study

Summary

RATIONALE: Aurora B/C kinase inhibitor GSK1070916A (GSK1070916A) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of GSK1070916A in treating patients with advanced solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

Aurora B/C kinase inhibitor GSK1070916A

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

diffusion-weighted magnetic resonance imaging + PET CT

RADIATION

fludeoxyglucose F 18 dynomic contrast

Sponsors & Collaborators

Principal Investigators

  • Chris Twelves, MD, BMedSci, FRCP · Leeds Cancer Centre at St. James's University Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118611 on ClinicalTrials.gov